[Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera®/Gilenya®) for the treatment of multiple sclerosis].
Kenji
K
Chiba
Narihiko
N
Yoshii
D000284:Administration, Oral; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy / Q000517:prevention & control; D000068876:Fingolimod Hydrochloride; D006801:Humans; D008214:Lymphocytes / Q000502:physiology; D008246:Lysophospholipids / Q000502:physiology; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011409:Propylene Glycols / Q000008:administration & dosage* / Q000494:pharmacology*; D049349:Receptors, Lysosphingolipid / Q000037:antagonists & inhibitors; D055502:Secondary Prevention; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000502:physiology; D058504:Th17 Cells / Q000276:immunology
D008246:Lysophospholipids; D011409:Propylene Glycols; D049349:Receptors, Lysosphingolipid; C060506:sphingosine 1-phosphate; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine